This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligibility Criteria for objective #1:
Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
Patients who are undergoing a planned PET-CT scan at main campus of MSK.
Patients must be ≥ 18 years old
Eligibility Criteria for objective #2:
Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
Patients with metastatic prostate or head and neck cancer.
Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
Patients must be ≥ 18 years old
Eligibility Criteria for objective #3:
Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
Patients must be ≥ 18 years old
You may not be if
Patients who suffer from claustrophobia.
Women who are pregnant or breast-feeding.
Patients \< 18 years of age
Clareo Health | A Study of a New PET Scanner in People With Cancer
